Other ways to search: Events Calendar | UTHSC

UTHSC-led team lands cancer immunotherapy grant


Cancer immunotherapy is a form of cancer treatment that uses the body’s immune system to prevent, control, and eliminate cancer, and it’s become a popular method. But it often fails to cure patients, as the cancer cells can sidestep and inhibit the body’s anti-tumor response. Now, however, a team at the University of Tennessee Health Science Center (UTHSC) believes it can improve the treatment — and it’s received a multimillion-dollar grant to do so. According to a press release, a UTHSC-led group has received a $3.16 million grant from the National Cancer Institute (NCI), to develop a drug that boosts the immune system response in cancer patients, so it can destroy tumor cells. Gabor Tigyi, Ph.D., the Harriet Van Vleet Endowment Professor in the Department of Physiology is the lead investigator on the project; and Sue Chin Lee, Ph.D., another professor in the department, is a principal investigator.

Top Publishers